Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

BACKGROUND: Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein recently approved for prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). The objective of this report is to summarize results from an interim analysis of an ongoing long...

Descripción completa

Detalles Bibliográficos
Autores principales: Farkas, Henriette, Stobiecki, Marcin, Peter, Jonny, Kinaciyan, Tamar, Maurer, Marcus, Aygören‐Pürsün, Emel, Kiani‐Alikhan, Sorena, Wu, Adrian, Reshef, Avner, Bygum, Anette, Fain, Olivier, Hagin, David, Huissoon, Aarnoud, Jeseňák, Miloš, Lindsay, Karen, Panovska, Vesna Grivcheva, Steiner, Urs C., Zubrinich, Celia, Best, Jessica M., Cornpropst, Melanie, Dix, Daniel, Dobo, Sylvia M., Iocca, Heather A., Desai, Bhavisha, Murray, Sharon C., Nagy, Eniko, Sheridan, William P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221587/
https://www.ncbi.nlm.nih.gov/pubmed/34161665
http://dx.doi.org/10.1002/clt2.12035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221587/
https://www.ncbi.nlm.nih.gov/pubmed/34161665
http://dx.doi.org/10.1002/clt2.12035

Ejemplares similares